Study of the Relationship Between Kras Gene Mutations and Gender, Age and Race in Colorectal Cancer Patients Residing in the Republic of Kazakhstan

Kaidarova, Dilyara; Smagulova, K.; Chichua, N.; Уколова, Е. А.; Kurmankulova, A.; Ишкинин, Е.И.

doi:10.21294/1814-4861-2020-19-1-82-89

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several research today showed that mutations in the RAS family of genes especially the KRAS are linked to around a third of all malignancies; however, the incidence of the gene mutations varies greatly depending on the kind of cancer: often seen to be 40% in colorectal cancer, 15-20% in non-small-cell lung cancer, and 95% in pancreas carcinoma [ 44 ]. Only a few individuals diagnosed with colorectal cancer would be opportune to receive curative surgery if detected early because, at the time of consult with the surgeon, it is already in the late stage wherein the prognosis is poor.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population

Afolabi

Salleh

Zunita

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Globally, colorectal carcinoma (CRC) is the third most common cancer and the third major cause of cancer-related death in both sexes. KRAS and BRAF mutations are almost mutually exclusively involved in the pathogenesis of CRC. Both are major culprits in treatment failure and poor prognosis for CRC. Method. A systematic review and meta-analysis of various research was done following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. This trial is registered with PROSPERO CRD42021256452. The initial search included 646 articles; after the removal of noneligible studies, a total of 88 studies was finally selected. Data analysis was carried out using OpenMeta Analyst and Comprehensive Meta-Analysis 3.0 (CMA 3.0) software to investigate the prevalence of KRAS and BRAF mutations among patients with CRC in Asia. Results. The meta-analysis comprises of 25,525 sample sizes from Asia with most being male 15,743/25525 (61.7%). Overall prevalence of KRAS mutations was (59/88) 36.3% (95% CI: 34.5-38.2) with I 2 = 85.54 % ( P value < 0.001). In 43/59 studies, frequency of KRAS mutations was majorly in codon 12 (76.6% (95% CI: 74.2–78.0)) and less in codon 13 (21.0% (95% CI: 19.1-23.0)). Overall prevalence of BRAF mutations was 5.6% (95% CI: 3.9-8.0) with I 2 = 94.00 % ( P value < 0.001). When stratified according to location, a higher prevalence was observed in Indonesia (71.8%) while Pakistan has the lowest (13.5%). Conclusion. Total prevalence of KRAS and BRAF mutations in CRC was 36.6% and 5.6%, respectively, and the results conformed with several published studies on KRAS and BRAF mutations.

show abstract

Section: Discussionmentioning

confidence: 99%